iRhythm Holdings (IRTC) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 revenue rose 14.9% year over year to $221.6 million, roughly in line with the analyst consensus of about $222.3 million.
• Adjusted (non-GAAP) earnings per share (EPS) reached $0.82, far above the roughly $0.05 analysts had expected, driven by a sharp margin expansion.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed to $51.18 million, a 23.1% margin that nearly doubled the consensus estimate.
• Full-year revenue guidance was raised to $890 million–$895 million, but the midpoint still came in below Wall Street's forecast, contributing to the stock's decline.
• On a GAAP (Generally Accepted Accounting Principles) basis, the company posted a net loss as a one-time litigation settlement charge weighed on results.
• For more information on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages.
• Explore Trending AI Robots for automated trading insights.

Earnings Context and Why It Matters

iRhythm Holdings is a digital healthcare company known for its Zio cardiac monitoring platform, and its quarterly results offer a read on demand for ambulatory heart monitoring across cardiology, primary care, and international markets. This report carries added weight because it is the first since the company closed its acquisition of VitalConnect, broadening its portfolio into mobile cardiac telemetry (MCT), a form of continuous heart-rhythm monitoring. Investors were also watching whether the company could sustain the momentum of recent quarters, when revenue growth and margin improvement consistently outpaced expectations. The reaction to the report shows that strong profit execution alone was not enough to satisfy a market focused on the forward revenue trajectory.

Reported Results

iRhythm Holdings reported third quarter 2026 revenue of $221.6 million, up 14.9% year over year and essentially in line with the consensus estimate of about $222.3 million. Adjusted (non-GAAP) EPS came in at $0.82, a substantial beat versus the roughly $0.05 analysts had modeled, and a dramatic improvement from a loss of $0.06 per share in the prior-year quarter.

Profitability was the standout theme. Adjusted EBITDA reached $51.18 million, representing a 23.1% margin, well above the $27.82 million consensus. Gross margin expanded to 74.2%, up roughly 310 basis points from a year earlier, helped by volume growth, operational efficiencies, and a one-time tariff refund benefit.

However, the bottom line on a GAAP basis swung to a net loss of approximately $29.9 million, or $0.90 per diluted share, reflecting a one-time litigation settlement charge of about $49.8 million. For the full year, management raised revenue guidance to a range of $890 million–$895 million (up from a prior midpoint of $885 million) and guided adjusted EBITDA margin to 15.5%–16.0%. The updated revenue midpoint of $892.5 million remained roughly 1.5% below consensus, a key source of investor disappointment. The guidance includes about $16 million of expected VitalConnect revenue contribution through year-end.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are looking to identify setups across the healthcare and technology sectors, the AI Screener can help streamline your research.

Market Reaction and Investor Sentiment

Despite a significant earnings beat on the bottom line, iRhythm Holdings shares fell roughly 12.4% following the report. The decline highlights how the market weighed the company's conservative full-year revenue outlook against the strong quarterly profit performance. Investors appear to have focused on the gap between the raised guidance midpoint and the higher consensus forecast, as well as the one-time litigation charge that pushed GAAP results into a loss. The closing of the VitalConnect acquisition was framed by management as a long-term growth opportunity, but the near-term contribution embedded in guidance was more modest than some investors had hoped. Overall, sentiment reflects a tension between improving operational profitability and questions about the pace of future revenue growth.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether iRhythm Holdings can close the gap between its guidance and Street expectations while continuing to expand margins. Management guided full-year revenue of $890 million–$895 million and an adjusted EBITDA margin of 15.5%–16.0%, with the VitalConnect integration expected to add about $16 million in revenue through the end of 2026.

Several factors will shape the coming quarters. First, the pace of Zio Monitor volume growth across care settings remains central, since demand has consistently exceeded internal expectations. Second, the integration of VitalConnect and its FDA-cleared MCT device will be a key test of management's ability to broaden its cardiac-monitoring portfolio without disrupting core execution.

Margin trajectory is another area to monitor, particularly whether gross-margin gains from automation and scale can be sustained without one-time benefits. Finally, the one-time litigation settlement and any related regulatory or legal developments could continue to influence reported GAAP results and cash flow. Operating cash flow came in at just $4.44 million in the quarter, leaving liquidity and expense discipline as important watchpoints heading into the fourth quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations